Momenta To Take Generic Lovenox Fight To Supreme Court

Law360, New York (November 20, 2012, 5:05 PM EST) -- Momenta Pharmaceuticals Inc. plans to seek U.S. Supreme Court review of a Federal Circuit decision that overturned an injunction against Amphastar Pharmaceuticals Inc. and said a lower court had interpreted the Hatch-Waxman Act's safe harbor provision too narrowly, Momenta said Tuesday.

Momenta announced that the Federal Circuit had denied its bid for an en banc rehearing to reconsider a 2-1 Federal Circuit panel decision from Aug. 3, which nixed an injunction blocking Amphastar and its distribution partner Watson Pharmaceuticals Inc. from selling a generic version of...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.